Shaad E. Abdullah
YOU?
Author Swipe
Unusual retroperitoneal presentation of a Giant mesenteric cyst in a pediatric patient: Surgical case report Open
Surgical excision serves both diagnostic and therapeutic purposes. While outcomes are generally favorable, the underlying mechanisms of these lesions remain unclear, highlighting the need for further research.
Cutaneous myiasis complicating squamous cell carcinoma: a case report with literature review Open
Myiasis is derived from the Greek word “myia”, which means “fly”. Zumpt, a German entomologist, defined this condition as the infestation of living humans and vertebrate animals by dipterous larvae that feed on living and dead host tissue,…
The Culture of Conspicuous Consumption of Food Among University Students Open
The Conspicuous consumption of food is primarily the expense of expensive products to indicate a free income and gain a social status in return. The main question of this study, which includes the problem of the study, is there a culture o…
Ocular Manifestations in Psoriasis. The Importance of Ophthalmological Examination Open
Psoriasis is a chronic, inflammatory, immune-mediated skin disease affecting 1-3% of the adult population. It mainly involves the skin, nails, and joints. However, psoriasis can be associated with several comorbidities, including ocular co…
Molecular Profiling and Pathological Evaluation of Bovine Papillomavirus‐1 in Cattle in Al‐Sharkia, Egypt Open
Bovine papillomatosis virus (BPV) is a prevalent cutaneous oncogenic viral disease in cattle, causing economic losses due to reduced milk production, poor carcass quality, and hide damage. Despite BPV’s economic significance, molecular inf…
View article: Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action Open
Tebentafusp is a gp100xCD3-bispecific ImmTAC designed to redirect polyclonal T cells against cells presenting the melanocyte lineage-specific antigen gp100 on HLA-A∗02:01. Skin-related adverse events, predominantly rash, are frequent and o…
CD-20-0047R2_Supplementary_Figure_2.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Figure S2
Data from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-st…
CD-20-0047R2_Supplementary_Figure_3.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Figure S3
View article: Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Antitumor efficacy of TNFRSF agonist immunotherapies in CT26 STK11wt or KO mice. Survival of mice engrafted with (A) CT26 WT or (B) CT26 STK11 KO clone 26C16 treated with isotype control antibodies, anti-PD-L1 plus anti-CTLA-4 mAbs or immu…
CD-20-0047R2_Supplementary_Figure_1.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Figure S1
View article: Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Characterization of innate and adaptive immune cell recruitment to CT26 STK11 KO tumors compared to CT26 WT. (A) Work flow for single cell RNA (scRNA) analysis of CD45+ cells isolated from CT26 WT and STK11 KO clones. Data analysis includi…
Data from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n = 978) and on-treatment (n = 171) ctDNA samples across 16 advanced-st…
View article: Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
List of genes differentially expressed in STK11mut vs STK11wt tumors.
View article: Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Suppressive activity of MDSCs isolated from CT26 WT or CT26 SKT11 KO tumors and pharmacological reversal by STAT3 ASO treatment in the CT26 WT model. (A) Percentage of naive T cell proliferation by anti-CD3/CD28/IL2 stimulation in the pres…
View article: Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S5 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the monocyte-macrophage-DC subpopulations identified in Supplementary Figure 5H. Only genes with adjusted p-value 0.3 were included. gene, gene name; p_val, p-value calculated based on Wilcoxon test; avg_logFC, log fold-ch…
View article: Supplementary Figure S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Characterization of STAT3 phosphorylation in the CT26 STK11 KO model and from primary human NSCLC tumors. (A) Representative multispectral fluorescence imaging of phosphorylated murine STAT3 (pSTAT3), CD45, CD163, and nuclei (DAPI), as ind…
View article: Supplementary Table S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Kaplan-Meier analysis using a log rank (Mantel-Cox) test to compare survival among the treatment groups represented in Figure 5. A total of 9 comparisons between groups were conducted. P-values were not adjusted for multiple comparisons.
View article: Supplementary Figure S11 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S11 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Efficacy of anti-IL6 mAb in CT26 STK11 KO model. (A) Survival of mice engrafted with 26C16 and treated as indicated. Isotype vs anti-PD-L1 plus anti-CTLA-4, p = 0.0020; Isotype vs anti-IL6 plus anti-PD-L1 plus anti-CTLA-4, p = 0.034; anti-…
View article: Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S7 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Time to 50% survival, in days, for mice engrafted with EMT6 tumors left untreated or treated with isotype control Ab or anti-PD-L1 plus anti-CTLA-4.
CD-20-0047R2_Supplementary_Figure_5.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Figure S5
View article: Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S9 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
CPI efficacy in EMT6 STK11wt, KO, and KO/KI tumors. (A) Western blotting of STK11, phosphorylated AMPK (p-AMPK), total AMPK, and actin in lysates from wild-type EMT6 cells (EMT6 WT), STK11 CRISPR KO clone (EMT6 KO) and from STK11 KO clone …
CD-20-0047R2_Supplementary_Appendix.docx from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Supplementary Materials and Methods
View article: Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Marker genes for the lymphocyte subpopulations identified in Supplementary Figure 6. Only genes with adjusted p-value 0.3 were included. gene, gene name; p_val, p-value calculated based on Wilcoxon test; avg_logFC, log fold-change of the a…
View article: Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Dependence of STAT3 ASO and combination treatment efficacy on CD8+ or CD4+ T cells in CT26 STK11 KO clone 26C16. Efficacy of STAT3 ASO, CPIs, and combination treatments as indicated in mice pre-treated with (A) control antibody, (B) anti-C…
View article: Supplementary Table S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Table S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Cytokines and other soluble factors evaluated in the baseline serum of patients with STK11mut or STK11wt tumors.
CD-20-0047R2_Supplementary_Figure_4.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade Open
Figure S4
View article: Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S8 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Antitumor efficacy of TNFRSF agonist immunotherapies in CT26 STK11wt or KO mice. Survival of mice engrafted with (A) CT26 WT or (B) CT26 STK11 KO clone 26C16 treated with isotype control antibodies, anti-PD-L1 plus anti-CTLA-4 mAbs or immu…
View article: Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown Open
Association between STK11 mutation and patient prognosis. In TCGA, STK11 mutations do not predict NSCLC OS.